Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0JSOZ)

Drug Name	PMID26924192-Compound-32 Drug Info
Cross-matching ID	PubChem CID 91864635 TTD Drug ID DM0JSOZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bromodomain-containing protein 4 (BRD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CPI-0610	DMPXOYJ	Myelofibrosis	2A20.2	Phase 3	[2]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
PLX2853	DMX168L	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
RVX-208	DM1LO8K	Alzheimer disease	8A20	Phase 1/2	[2]
INCB57643	DMBGU7V	Advanced malignancy	2A00-2F9Z	Phase 1/2	[3]
ABBV-744	DMTEA9C	Acute myeloid leukaemia	2A60	Phase 1	[3]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[4]
GSK525762	DMPAWBN	Haematological malignancy	2B33.Y	Phase 1	[2]
TEN010	DM4UOY5	Advanced solid tumour	2A00-2F9Z	Phase 1	[2]
AZD5153	DMW4GM2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Extracellular signal-regulated kinase 5 (ERK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID26924192-Compound-30	DMWXNIJ	N. A.	N. A.	Patented	[1]
PMID26924192-Compound-33	DM9NWXM	N. A.	N. A.	Patented	[1]
XMD8-92	DMZIHKY	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain-containing protein 4 (BRD4)	TTRA6BO	BRD4_HUMAN	Inhibitor	[1]
Extracellular signal-regulated kinase 5 (ERK5)	TTU6FSC	MK07_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
2	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
5	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.